31 results
8-K
EX-99.2
AXLA
Axcella Health Inc.
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
Chronic inflammatory signalling 1. Singh et al, Am J Physiol Cell Physiol , 2020 2. Ajaz et al, Am J Physiol , 2020 3. Gibellini et al, EMBO Molecular … Medicine, 2020 4. Cassar M et al, EClinicalMedicine, 2022 Chronic fatigue syndrome – mitochondrial dysfunction
Potential mechanisms underlying Long
8-K
EX-99.2
AXLA
Axcella Health Inc.
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
and safely treat complex, chronic diseases using oral, multi-targeted therapies composed of endogenous molecules?
© 2021 Axcella Health Inc. All rights … with AE rates comparable to placebo Modality utilizing inherently safe amino acids substantially removes concerns about chronic use
© 2021 Axcella
8-K
EX-99.1
AXLA
Axcella Health Inc.
10 Jan 22
Other Events
8:00am
clinical data demonstrate the potential to harness the power of EMMs to tackle complex chronic conditions — Improving neurocognition — Rebalancing IEMs … to date1 23% (~70M) of COVID patients report Long COVID conditions and symptoms2 Most commonly reported symptom: Chronic fatigue, experienced by most Long
8-K
EX-99.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
that demonstrate the potential to harness the power of EMMs to tackle prevalent chronic conditions and I believe the company is now well positioned
8-K
AXLA
Axcella Health Inc.
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
is a validated patient reported outcome measure of fatigue that has been used in measuring patient impact in fatigue states such as chronic fatigue syndrome
8-K
EX-99.1
3cyn17g5j691rd
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.2
odmuxchm99jj8xt4
29 Sep 22
Regulation FD Disclosure
9:15am
S-1
g4olbgmbwgg0werq1d6
12 Apr 19
IPO registration
7:02am
424B4
ony7 fpsozm
9 May 19
Prospectus supplement with pricing info
4:29pm
DRS/A
krx i37nzoz20ht
15 Mar 19
Draft registration statement (amended)
12:00am
DRS
66snweadbknfdcrt
28 Jan 19
Draft registration statement
12:00am
10-K
mv4oo
23 Mar 20
Annual report
4:12pm
424B4
zx4nffancvl
14 May 20
Prospectus supplement with pricing info
5:15pm
DRS
j8wj r86erxm
3 Apr 20
Draft registration statement
12:00am
424B5
y2r8pu41k7gb
13 Oct 22
Prospectus supplement for primary offering
7:55am
424B5
5fohn2p1lij pw
16 Mar 22
Prospectus supplement for primary offering
8:00am